OVERVIEW

Liver Cancer Summit 2020 is organized by European Association for the Study of the Liver (EASL) and will be held from Feb 06 - 08, 2020 at Prague, Czech Republic.

Who should attend?
• Basic scientists
• Clinical scientists
• Early career investigators
• Pharma companies
• Biotech companies

Description:
The meeting will address the latest developments in hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) that you as a practicing physician and/or scientist should know. This year for the first time, this successful meeting will have a new title “Liver Cancer Summit” instead of the well-known “HCC Summit” to reflect the growing preclinical and clinical data and rapidly changing treatment landscape of CCA in addition to HCC.

The biology of liver cancer remained obscure for many years. However, over the last period of time, an intense preclinical research shed new light on the molecular mechanisms involved in the malignant transformation of hepatic cells (mainly hepatocytes and cholangiocytes) and in their interaction with the stroma and immune system. In addition, new risk factors for liver cancer has been described and need to be considered. Moreover, clinical trials have identified novel perspectives and strategies for the accurate diagnosis, management and treatment for HCC and CCA. While these developments offer many new opportunities for your patients, it is becoming increasingly difficult to keep track and timely implement these changes into daily clinical practice and research projects. This multidisciplinary meeting is organized to provide an update on the current knowledge and future directions on the study of HCC and CCA, and its significance under a clinical point of view. Also, the aim of this multidisciplinary summit is to bring physicians and scientists together and promote the exchange of clinical knowledge, the discussion of controversial issues and the establishment of collaborations.

Why attend?
• To know the main features of the biology of liver cancers
• To know the principles of genetic defects as determinants of liver cancer
• To understand the mechanisms leading to malignant transformation of hepatic cells
• To understand the mechanisms that govern cell-to-cell interactions and their significance for disease progression
• To know the principles and correlations between immunology and liver cancers
• To understand the impact of novel biological and immunological evidences for the clinical managements of hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA)
• To illustrate the role of biomarkers in HCC and CCA
• To illustrate and understand novel aspects of personalized medicine
• To discuss the development of clinical trials between academia, pharma and regulatory agencies

Topics to be covered:
• Preclinical research on the mechanisms of malignant transformation of hepatic cells and of cell-to-cell interactions
• Basic and translational research on the biology, genetics, and immunology of HCC and CCA
• New developments in HCC and CCA management, including new targeted agents and recent data and implications for immunotherapy of HCC and CCA
• Personalized medicine
• The new challenge of microbiota and liver cancer
• Novel biomarker concepts in HCC and CCA
• Discussions on clinical trials between academia, pharma and regulatory agencies

Additional details will be posted as soon as they are available.